New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
about
The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.ALK: a tyrosine kinase target for cancer therapy.A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma.Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA.
P2860
New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
New therapeutic strategies in ...... liposomal siRNAs against ALK.
@ast
New therapeutic strategies in ...... liposomal siRNAs against ALK.
@en
type
label
New therapeutic strategies in ...... liposomal siRNAs against ALK.
@ast
New therapeutic strategies in ...... liposomal siRNAs against ALK.
@en
prefLabel
New therapeutic strategies in ...... liposomal siRNAs against ALK.
@ast
New therapeutic strategies in ...... liposomal siRNAs against ALK.
@en
P2093
P2860
P50
P356
P1433
P1476
New therapeutic strategies in ...... d liposomal siRNAs against ALK
@en
P2093
Annarita Di Fiore
Chiara Brignole
Chris Liang
Elisa Destafanis
James Gibbons
Laura Emionite
Michele Cilli
Xiaobao Xu
P2860
P304
28774-28789
P356
10.18632/ONCOTARGET.4342
P407
P577
2015-10-01T00:00:00Z